Brief: Kazia Therapeutics Announces Transformative Preclinical Data
11/06/2025 13:54
June 11 (Reuters) - Kazia Therapeutics Ltd KZIA.O: KAZIA THERAPEUTICS ANNOUNCES TRANSFORMATIVE PRECLINICAL DATA DEMONSTRATING PAXALISIB'S POTENTIAL TO OVERCOME IMMUNOTHERAPY RESISTANCE IN TRIPLE-NEGATIVE BREAST CANCER (TNBC) Source text: ID:nPn60mKLsa Further company coverage: KZIA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
Kazia drops on $40 mln equity offering to fund breast cancer drug
Kazia slides after breast cancer drug update, equity offering launch
Brief: Kazia Therapeutics Limited Announces Proposed Public Offering